Kronos Bio Inc (OQ:KRON)

Business Focus: Biotechnology & Medical Research

Mar 21, 2024 07:05 am ET
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth-quarter and full-year 2023 financial results. “In 2023, we made great progress across...
Mar 07, 2024 04:05 pm ET
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a plan to optimize its resource allocation, restructure, and extend runway to focus resources on key programs in the...
Mar 05, 2024 04:44 pm ET
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual...
Feb 27, 2024 04:05 pm ET
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th Annual Cowen Health Care Conference, taking place March 4-6, 2024, in Boston, Massachusetts....
Jan 25, 2024 08:00 am ET
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a streamlined leadership structure designed to focus on pipeline advancement and align with Kronos Bio’s current operating...
Dec 18, 2023 04:06 pm ET
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced an update on its pipeline. After a review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in...
Dec 04, 2023 08:00 am ET
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles...
Nov 27, 2023 04:05 pm ET
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Norbert Bischofberger, Ph.D., president and chief executive officer, Jorge DiMartino M.D., Ph.D., chief medical officer...
Nov 20, 2023 08:31 am ET
Thinking about buying stock in Arista Networks, Permian Resources, Riot Platforms, Central Puerto ADR, or Kronos Bio?
NEW YORK, Nov. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ANET, PR, RIOT, CEPU, and KRON.
Nov 13, 2023 04:05 pm ET
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third-quarter 2023 financial results. “This quarter, we made great strides in advancing our...
Nov 02, 2023 04:05 pm ET
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a plan to optimize its resource allocation, restructure, and contain costs in light of the positive preliminary safety and...
Nov 02, 2023 12:00 pm ET
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the presentation of positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742...
Oct 27, 2023 08:00 am ET
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742...
Oct 13, 2023 12:30 pm ET
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced positive preliminary data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 clinical trial of KB-0742 at the...
Oct 04, 2023 04:05 pm ET
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will host a conference call and webcast on Friday, October 13, 2023, at 4:30 p.m. ET., followed by a Q&A session....
Aug 17, 2023 08:00 am ET
Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that its Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign from his position to...
Aug 08, 2023 04:05 pm ET
Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and second-quarter 2023 financial results. “KB-0742 is the first molecule to emerge from our...
Jun 06, 2023 08:00 am ET
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Marc Besman Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance. Dr....
Jun 01, 2023 04:05 pm ET
Kronos Bio Announces Participation in Upcoming Investor Conferences
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: Jefferies...
May 10, 2023 04:05 pm ET
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and first-quarter 2023 financial results. "This quarter, we made significant strides in our...
Apr 24, 2023 04:05 pm ET
Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Roger Dansey, M.D., to the company’s Board of Directors. Dr. Dansey brings extensive experience in...
Apr 11, 2023 04:05 pm ET
Kronos Bio Announces Changes to Board of Directors
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Katherine Vega Stultz to its Board of Directors, replacing Otello Stampacchia, Ph.D., who stepped down as...
Mar 15, 2023 04:05 pm ET
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth-quarter and full-year 2022 financial results. “We have had an exciting start to 2023,...
Feb 28, 2023 04:05 pm ET
Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 43rd Annual Cowen Health Care Conference, taking place March 6-8, 2023, in Boston, Massachusetts....
Jan 09, 2023 07:00 am ET
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced today that it has entered into a discovery collaboration in the field of oncology with Genentech, a member of the Roche Group,...
Dec 11, 2022 10:00 am ET
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Societ
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, is presenting preclinical data that demonstrate anti-leukemic activity of the investigational spleen tyrosine kinase (SYK) inhibitor,...
Dec 07, 2022 04:05 pm ET
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Tria
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that data from the ongoing dose-escalation stage of its Phase 1/2 clinical trial of KB-0742, the company’s cyclin dependent...
Nov 22, 2022 04:05 pm ET
Kronos Bio Announces Participation in Upcoming Investor Conferences
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: Piper...
Nov 08, 2022 04:10 pm ET
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third-quarter 2022 financial results. In a press release issued earlier this afternoon, the...
Nov 08, 2022 04:05 pm ET
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the prioritization of its clinical portfolio to focus on the development of its next generation SYK inhibitor, lanraplenib,...
Oct 12, 2022 04:04 am ET
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present preclinical data in a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer...
Sep 06, 2022 04:05 pm ET
Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the H.C. Wainwright 24th Annual Global Investment Conference. An on-demand...
Aug 22, 2022 08:00 am ET
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in...
Aug 16, 2022 04:05 pm ET
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML
Aug 16, 2022 04:05 pm ET
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML
Aug 16, 2022 04:05 pm ET
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, today announced their agreement to develop a companion...
Aug 04, 2022 04:05 pm ET
Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today reported recent business progress and second-quarter 2022 financial results. “We are continuing to execute...
Jun 10, 2022 03:04 am ET
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, will present preclinical data today from studies of the company’s two novel investigational spleen tyrosine...
Jun 01, 2022 04:05 pm ET
Kronos Bio Announces Participation in Upcoming Investor Conferences
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced that President and Chief Executive Officer Norbert Bischofberger, Ph.D., will participate in...
May 17, 2022 07:00 am ET
Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the H.C. Wainwright Global Investment Conference. An on-demand webcast of the...
May 12, 2022 10:23 am ET
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced that its two novel investigational spleen tyrosine kinase (SYK) inhibitors, entospletinib and...
May 04, 2022 04:05 pm ET
Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today reported recent business progress and first quarter 2022 financial results. “We continued to advance our...
Apr 08, 2022 01:07 pm ET
Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today shared preclinical data on its internally discovered, highly selective, oral cyclin dependent kinase 9...
Mar 08, 2022 05:08 pm ET
Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced that it will present preclinical data on its internally discovered, highly selective, oral cyclin...
Mar 01, 2022 07:00 am ET
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the Cowen 42nd Annual Health Care Conference, a virtual event taking place March...
Feb 24, 2022 04:05 pm ET
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today reported recent business progress and fourth-quarter and full-year 2021 financial results. “We had a...
Feb 01, 2022 04:05 pm ET
Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced the appointment of Dr. Elizabeth Olek, DO, MPH, as senior vice president, Clinical Development....
Dec 17, 2021 07:00 am ET
Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies
BOSTON, Dec. 17, 2021 /PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million in limited partner capital commitments. The new fund, Omega Fund VII, L.P. ("Fund VII"), was oversubscribed, exceeding the firm's targeted raise of $500 million, and included strong support from both new and existing limited partners. With Fund VII, the firm will continue to execute on its strategy of creating and investing in life sciences companies in the
Dec 06, 2021 07:00 am ET
Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in the registrational Phase 3 AGILITY clinical trial of entospletinib, a selective...
Nov 29, 2021 07:00 am ET
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced positive data from the ongoing Phase 1/2 clinical trial of KB-0742, the company’s internally discovered, highly selective,...
Nov 24, 2021 07:00 am ET
Kronos Bio Announces Participation in Upcoming Investor Conferences
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: Piper...
Nov 11, 2021 04:05 pm ET
Kronos Bio Appoints Roshawn Blunt to Board of Directors
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Roshawn Blunt to the company’s Board of Directors. Ms. Blunt has more than 25 years of experience in the...
Nov 09, 2021 04:10 pm ET
Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third-quarter financial results. “As we approach the end of the year, we look forward to...
Nov 08, 2021 04:44 pm ET
Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year collaboration that provides Kronos Bio...
Nov 04, 2021 07:00 am ET
Kronos Bio Announces Participation in the BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology 
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Charles Lin, Ph.D., Senior Vice President, Biology, will participate in the Emerging Trends and Therapeutics in...
Sep 30, 2021 04:35 pm ET
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present preclinical data in a poster at the AACR-NCI-EORTC Virtual International Conference on Molecular...
Sep 14, 2021 08:00 am ET
Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Marni Kottle as senior vice president of Corporate Communications and Investor Relations. Ms. Kottle...
Sep 07, 2021 07:00 am ET
Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference 
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment...
Aug 12, 2021 04:05 pm ET
Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and second quarter financial results. “At our virtual R&D Day in May, we outlined our vision for...
Jul 27, 2021 08:00 am ET
Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug Application (IND) for lanraplenib...
May 26, 2021 08:00 am ET
Kronos Bio Announces Participation in Upcoming Investor Conferences
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: Jefferies...
May 25, 2021 08:00 am ET
Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, will host a virtual R&D Day today to detail the development strategy for its spleen tyrosine kinase (SYK) inhibitor portfolio, and highlight...
May 11, 2021 04:05 pm ET
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and first quarter financial results. “With continued progress in our preclinical and clinical...
May 06, 2021 08:00 am ET
Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the Bank of America Securities 2021 Health Care...
Apr 10, 2021 08:30 am ET
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today presented preclinical data for KB-0742, a highly selective, orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor being...
Mar 31, 2021 11:25 am ET
Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.
Kronos Bio, Inc. (Nasdaq: KRON) today commented on the passing of John C. Martin, Ph.D., board member and early investor in the company. “On behalf of the employees and Board of Directors at Kronos Bio, I am deeply saddened by John’s passing. An...
Mar 26, 2021 08:00 am ET
Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Taiyin Yang, Ph.D., to the company’s board of directors. Dr. Yang has more than four decades of...
Mar 23, 2021 04:05 pm ET
Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth quarter and full year 2020 financial results. “2020 was a transformational year for...
Mar 10, 2021 04:35 pm ET
Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that data from a pre-clinical study of KB-0742, a highly selective, orally bioavailable cyclin dependent kinase 9 (CDK9)...
Mar 04, 2021 07:00 am ET
Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)
Kronos Bio, Inc. (Nasdaq: KRON) today announced, following receipt of minutes from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), that the company will proceed with its plan to assess measurable residual disease (MRD)...
Feb 25, 2021 08:00 am ET
Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in the Phase 1/2 clinical trial of KB-0742, a highly selective, orally bioavailable...
Feb 22, 2021 08:00 am ET
Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the Cowen 41st Annual Health Care Conference, a virtual event taking place March 1-4, 2021. Kronos Bio...
Jan 26, 2021 08:00 am ET
Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of veteran biopharmaceutical executive Marianne De Backer, Ph.D., to the company’s board of directors. She...
Dec 08, 2020 08:00 am ET
Kronos Bio Appoints Pasit Phiasivongsa, Ph.D., as Senior Vice President, Pharmaceutical Development
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Pasit Phiasivongsa, Ph.D., as senior vice president, pharmaceutical development. Dr. Phiasivongsa brings...
Dec 07, 2020 08:00 am ET
Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced U.S. Food and Drug Administration (FDA) clearance of the company’s Investigational New Drug (IND) application for KB-0742, a...
Nov 23, 2020 08:00 am ET
Kronos Bio Announces Participation in Upcoming Investor Conferences
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in the following investor conferences: A virtual fireside chat at...
Nov 18, 2020 08:00 am ET
Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third quarter 2020 financial results. “Kronos Bio experienced transformational growth in 2020....
Nov 11, 2020 08:00 am ET
Kronos Bio Announces Participation in the Jefferies Virtual London Healthcare Conference
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the Jefferies Virtual London Healthcare...
Oct 22, 2020 08:00 am ET
Kronos Bio Announces Publication of Preclinical Study Results for Investigational CDK9 Inhibitor KB-0742 in Cell Chemical Biology
Kronos Bio, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced results of a preclinical...
Oct 14, 2020 04:05 pm ET
Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kronos Bio, Inc. (Nasdaq: KRON), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced the...
Oct 08, 2020 08:00 pm ET
Kronos Bio Announces Pricing of Initial Public Offering
Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced the pricing of its...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.